APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

NCT ID: NCT02210468

Last Updated: 2015-08-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2016-12-31

Brief Summary

The mechanism of Osteoarthritis (OA) is complex, however the investigators know that cartilage breakdown follows changes in certain cells in the cartilage called chondrocytes, leading to proteases that break down cartilage. There is a protein in the human blood called alpha-2-macroglobulin that can trap these proteases and prevent the breakdown of cartilage. Cytonics developed a device that use the patient's own blood to remove all cells and concentrate alpha-2-macroglobulin to be injected in the painful knee due to osteoarthritis.

Conditions

Pain; Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

APIC-CF 4cc,

APIC-CF 4cc, once at first day

Group Type: EXPERIMENTAL

APIC-CF, 4 cc

Intervention Type: DEVICE

APIC-CF, 2cc

APIC-CF, 2cc, one at first day

Group Type: EXPERIMENTAL

APIC-CF, 2 cc

Intervention Type: DEVICE

Saline

Group Type: PLACEBO_COMPARATOR

Placebo Comparator: Saline

Intervention Type: OTHER

Placebo Comparator: Saline

Interventions

APIC-CF, 4 cc

Intervention Type: DEVICE

APIC-CF, 2 cc

Intervention Type: DEVICE

Placebo Comparator: Saline

Placebo Comparator: Saline

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. The patient provides signed written informed consent

2. The patient is willing and able to complete effectiveness and safety questionnaires and is able to read and understand study instructions in English.

3. Patient is a male or female aged between 21 - 70 years of age at the time of informed consent.

4. Patient is ambulatory (assistive devices allowed if used 4 weeks or more prior to Screening).

5. Patient has symptomatic OA in the target knee

6. Patient has a radiographic confirmation of OA at the target knee prior to screening with a grade II or III score on the K-L grading scale (Kellgren, 1957)using radiographs performed within 24 weeks of Screening

7. The patient has knee pain as demonstrated by a score of ≤3 on the KOOS pain subscale

8. The patient has venous access sufficient for APIC-CF production

Exclusion Criteria

1. The patient has any of the following:

• Grade 4 score on the K-L grading scale for the target knee
• Grade 3 score on the K-L grading scale and exhibits at least one Grade 4 characteristic (large osteophytes, marked narrowing of joint space, severe sclerosis, or definite deformity of bone contour).
• Acute fracture of the lower limb.

2. Medical history of severe bone disease (e.g., osteoporosis, osteonecrosis, joint deformity, instability, or septic arthritis).

3. The patient is categorized as grossly obese, defined as body mass index (BMI) greater than 35 kg/m2

4. Hemoglobin values <11 g/dL

5. Pregnant or breastfeeding women

6. Has clinically apparent tense effusion of the target knee.

7. Has had chondrocyte transplantation or reconstruction of ligaments in the target knee.

8. Has received an intra-articular injection(s) into any joint (e.g., corticosteroids or chondroprotective agents) within 60 days prior to Screening. Subjects receiving a corticosteroid injection during the study will be withdrawn from the study.

9. Has had surgery to the target knee within 12 months or arthroscopy of the target knee within 90 days prior to Screening.

10. Has an inflammatory disease of either knee other than OA (e.g., rheumatoid arthri septic arthritis).

11. Has another disease that can affect the health of the knee (e.g., chronic hemochromatosis; sickle cell anemia; arthropathies of systemic diseases such as chondrocalcinosis, gout, pseudogout, psoriasis, hemophilia, and infectious diseases of the joints).

12. Has significant joint infection in the target knee or inflammatory or skin disorder in the injection area of the target knee.

13. Septic arthritis in any joints within 1 year prior to screening;

14. Has fibromyalgia, anserine bursitis, lumbar radiculopathy, neurogenic or vascular claudication, vascular insufficiency of lower limbs, or peripheral neuropathy severe enough to interfere with the study evaluations.

15. Patella femoral instability

16. Patients with a history of cartilage allograft, autograft or microfracture in the study knee

17. Patients with a history of any type of blood coagulation or bleeding disorder, currently taking warfarin or other parental anticoagulant therapy or history of DVT/PE during <1 year of Screening.

18. Has a systemic or other disease or significant liver function test result from screening that, in the opinion of the investigator, would interfere with study evaluation or have an impact on the balance of benefits and risks of study treatment.

19. Diseases that may interfere:

• type 1 diabetes
• immunodeficiency syndrome
• significant cardiovascular, renal, or liver disease
• severe anemia
• severe thrombocytopenia
• severe infectious disease with or without fever.
• any significant chronic skin disorders, active skin or soft tissue infection that could interfere with the evaluation of the injection site.
• mal-alignment/deformity of the leg
• active asthma that may require periodic treatment with steroids during the study period
• active malignancy receiving treatment, or prior history of any malignancy, with the exception of basal cell carcinoma of the skin treated more than 1 year ago

20. Patients with psychiatric or neurological disorders including cognitive impairment or inability to provide informed consent

21. Incarcerated or confined patients

22. Medical-legal, personal injury, ongoing litigation or worker's compensation claim

23. History of drug abuse

24. Use of investigational drug, device, or biologic within 12 weeks of screening

25. Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cytonics Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

IRC Clinical

Townsend, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Gaetano Scuderi, MD

Role: CONTACT

scuderimd@aol.com

561-575-4451 ext. 1

Facility Contacts

Kendra Barton, RN, BSN

Role: primary

kendra.barton@ircclinical.com

443-275-1599

Other Identifiers

Cyt300-01

Identifier Type: -

Identifier Source: org_study_id